Advanced search×
×

Clinical Therapeutics

Print ISSN
0149-2918
Electronic ISSN
1879-114X
Impact factor
2.551
Publisher
Sciencedirect
URL
http://www.sciencedirect.com/science/journal/01492918
Usage rank
431
Article count
4656
Free count
20
Free percentage
0.00429553
PDFs via platforms
Gale, Ingenta, Rcgp, and Sciencedirect from 1995

  1. First Time Compliance Inspections to Evaluate an Artificial Trans Fat Ban in Nassau County

    Clinical Therapeutics 36(3):333 (2014) PMID 24636819

    Background In 2007, Nassau County, New York, restricted the use of artificial trans fats in food establishments licensed by the Nassau County Department of Health (NCDH). The regulation took effect April 1, 2008.
  2. Long-term patterns of use and treatment failure with anticholinergic agents for overactive bladder.

    Clinical Therapeutics 35(11):1744 (2013) PMID 24091072

    Overactive bladder (OAB) involves a complex set of symptoms with a lifetime prevalence of any symptom in ~30% of women and 20% of men. Anticholinergic agents are associated with poor medication persistence in OAB treatment. This study evaluated the long-term patterns of use and treatment failure in...
  3. Reducing the pain of microemulsion propofol injections: a double-blind, randomized study of three methods of tourniquet and lidocaine.

    Clinical Therapeutics 35(11):1734 (2013) PMID 24161288

    We concluded that intravenous retention of lidocaine with the application of a rubber tourniquet under venous engorgement of the arm reduces the incidence and intensity of MP injection pain. Clinical trial registry: UMIN000010725. © 2013 Elsevier HS Journals, Inc. All rights reserved....
  4. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.

    Clinical Therapeutics 35(11):1850 (2013) PMID 24156821 PMCID PMC3917677

    Anti-tumor necrosis factor agents (anti-TNFs) have changed the course of rheumatoid arthritis (RA) for more than a decade. Use of these medications often results in remission, or at least low disease activity (LDA), but at a substantial cost. It has been postulated that discontinuation of these medi...
  5. Single-dose pharmacokinetic properties, bioavailability, and tolerability of two lamivudine 100-mg tablet formulations: a randomized crossov...

    Clinical Therapeutics 35(10):1546 (2013) PMID 24011635

    Lamivudine is used in the treatment of HIV and chronic hepatitis B (HBV) infections. Since 1999, at least 2 million Chinese HBV patients have been treated with lamivudine, but there are limited studies on the pharmacokinetics and safety of the drug in Chinese populations. This study was designed to...
  6. Pharmacokinetic interactions between eperisone hydrochloride and aceclofenac: a randomized, open-label, crossover study of healthy Korean me...

    Clinical Therapeutics 35(10):1528 (2013) PMID 24050970

    Eperisone hydrochloride, a centrally acting muscle relaxant, is a calcium antagonist that causes vasodilation and antispastic actions. Aceclofenac, an anti-inflammatory analgesic and antipyretic drug, has similar efficacy and improved gastrointestinal tolerance compared with other nonsteroidal anti-...
  7. 11th European association for clinical pharmacology and therapeutics congress, 2013.

    Clinical Therapeutics 35(10):1475 (2013) PMID 24139418

  8. Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide...

    Clinical Therapeutics 35(8):1162 (2013) PMID 23911260

    LX4211 is a first-in-class dual inhibitor of sodium-dependent glucose cotransporters 1 and 2 (SGLT1 and SGLT2). SGLT1 is the primary transporter for glucose absorption from the gastrointestinal tract, and SGLT2 is the primary transporter for glucose reabsorption in the kidney. SGLT1 inhibition reduc...
  9. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.

    Clinical Therapeutics 35(7):1005 (2013) PMID 23831360

    We selected patients who were being treated following the therapeutic recommendations of the National Osteoporosis Foundation or the guideline for glucocorticoid-induced osteoporosis recommended by the American College of Rheumatology. Adherence was determined by compliance and the persistence ratio...
  10. Descriptive comparison of drug treatment-persistent, -nonpersistent, and nondrug treatment patients with newly diagnosed attention deficit/h...

    Clinical Therapeutics 35(5):673 (2013) PMID 23587606

    Attention deficit/hyperactivity disorder (ADHD) is a heterogeneous behavioral disorder commonly found in children, with serious lifetime health and social consequences for both children and their parents. Public awareness of ADHD in Germany has increased in the past decade, but little is known about...